Drug Trial Radar · NCT05819775
CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema
Last checked: Nov 20, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
May 30, 2023
Primary completion
Nov 19, 2025
Study completion Nov 19, 2025
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Apr 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.
Conditions
- Hereditary Angioedema (HAE)
Interventions
CSL312Biological
Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAE)Time frame: Up to Month 12
- Percentage of Participants With TEAETime frame: Up to Month 12
- Number of TEAETime frame: Up to Month 12
- TEAE Rates Per InjectionTime frame: Up to Month 12
- TEAE Rates Per Participant-YearTime frame: Up to Month 12
- Maximum Concentration (Cmax) of CSL312 at Steady-stateTime frame: Up to Month 12
- Trough Concentration (Ctrough) of CSL312 at Steady-stateTime frame: At Months 3, 4, 6, 9, 10, and 12
- Time to Maximum Concentration (Tmax) of CSL312 at Steady-StateTime frame: Up to Month 12
Locations
13 sites in 5 countries. Site status is shown where the registry gives one.
Research Solutions of Arizona
Litchfield Park, Arizona
Medical Research of Arizona
Scottsdale, Arizona
Donald S. Levy M.D.
Orange, California
Raffi Tachdjian MD, Inc.
Santa Monica, California
Bernstein Clinical Research
Cincinnati, Ohio
PennState Health Milton S. Hershey Medical Center
Hershey, Pennsylvania
AARA Research Center
Dallas, Texas
Campbelltown Hospital, Western Sydney University
Campbelltown, Australia
Ottawa Allergy Research Corp
Ottawa, Canada
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
HZRM Hämophilie Zentrum Rhein Main GmbH
Frankfurt am Main, Hesse, Germany
Barzilai University Medical Center
Ashkelon, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.